Search research articles
Contact Us
Filters
Showing results (1-10 of 113) with videos related to
Page
of 12
Sort By:
Clinical Chemistry and Laboratory Medicine
|
July 10, 2007
Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice
Vangelis G Manolopoulos
Pharmacology
|
October 23, 2004
Atorvastatin and simvastatin decrease the uptake of acetylated low-density lipoprotein by human monocytes
Anna Tavridou, Vangelis G Manolopoulos
Pharmacogenomics
|
October 26, 2022
The revolution of pharmaco-omics: ready to open new avenues in materializing precision medicine?
Georgia Ragia, Vangelis G Manolopoulos
Pharmacogenomics
|
November 27, 2020
Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry
Georgia Ragia, Vangelis G Manolopoulos
Expert Opinion on Therapeutic Patents
|
May 22, 2009
Inhibitors of 5-lipoxygenase activating protein: WO 2008/030369
Anna Tavridou, Vangelis G Manolopoulos
European Journal of Pharmacology
|
November 24, 2004
Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo
Anna Tavridou, Vangelis G Manolopoulos
European Journal of Clinical Pharmacology
|
July 23, 2020
Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies
Georgia Ragia, Vangelis G Manolopoulos
Pharmacogenomics
|
March 28, 2018
From Homer and Hippocrates to modern personalized medicine: is there a role for pharmacoepigenomics in the treatment of alcohol addiction?
Georgia Ragia, Vangelis G Manolopoulos
Current Pharmaceutical Biotechnology
|
February 28, 2017
Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond
Georgia Ragia, Vangelis G Manolopoulos
Current Drug Metabolism
|
March 20, 2024
Fluoropyrimidine Toxicity: the Hidden Secrets of DPYD
Vangelis G Manolopoulos, Georgia Ragia
Page
of 12
Search research articles
Search
Showing results (1-10 of 113) with videos related to
Sort By:
Page
of 12
Clinical Chemistry and Laboratory Medicine
|
July 10, 2007
Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice
Vangelis G Manolopoulos
Pharmacology
|
October 23, 2004
Atorvastatin and simvastatin decrease the uptake of acetylated low-density lipoprotein by human monocytes
Anna Tavridou, Vangelis G Manolopoulos
Pharmacogenomics
|
October 26, 2022
The revolution of pharmaco-omics: ready to open new avenues in materializing precision medicine?
Georgia Ragia, Vangelis G Manolopoulos
Pharmacogenomics
|
November 27, 2020
Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry
Georgia Ragia, Vangelis G Manolopoulos
Expert Opinion on Therapeutic Patents
|
May 22, 2009
Inhibitors of 5-lipoxygenase activating protein: WO 2008/030369
Anna Tavridou, Vangelis G Manolopoulos
European Journal of Pharmacology
|
November 24, 2004
Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo
Anna Tavridou, Vangelis G Manolopoulos
European Journal of Clinical Pharmacology
|
July 23, 2020
Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies
Georgia Ragia, Vangelis G Manolopoulos
Pharmacogenomics
|
March 28, 2018
From Homer and Hippocrates to modern personalized medicine: is there a role for pharmacoepigenomics in the treatment of alcohol addiction?
Georgia Ragia, Vangelis G Manolopoulos
Current Pharmaceutical Biotechnology
|
February 28, 2017
Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond
Georgia Ragia, Vangelis G Manolopoulos
Current Drug Metabolism
|
March 20, 2024
Fluoropyrimidine Toxicity: the Hidden Secrets of DPYD
Vangelis G Manolopoulos, Georgia Ragia
Page
of 12